APO-RIVASTIGMINE PATCH 15 rivastigmine 13.3 mg/24 hours transdermal drug delivery system sachet

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

rivastigmine, Quantity: 27 mg

Inapatikana kutoka:

Arrotex Pharmaceuticals Pty Ltd

INN (Jina la Kimataifa):

Rivastigmine

Dawa fomu:

Drug delivery system, transdermal

Tungo:

Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica

Njia ya uendeshaji:

Transdermal

Vitengo katika mfuko:

30 sachets, 7 sachets

Dawa ya aina:

(S4) Prescription Only Medicine

Matibabu dalili:

APO-RIVASTIGMINE PATCH is indicated for the treatment of patients with mild, moderate and severe dementia of the Alzheimer?s type.

Bidhaa muhtasari:

Visual Identification: Circular 15cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 13.3 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Idhini hali ya:

Licence status A

Idhini ya tarehe:

2017-01-25